An interventional study of geko™ therapy in Surgery and Edema, sponsored by Firstkind Ltd. Completed at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Firstkind Ltd (part of Sky Medical Technology) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Edema with a site in Spain — 2 open to participants now, 2 under way, none of them phase 3. Edema · Spain.
Among the 13 studies in Edema with a site in Spain, this one is one of 2 that started in 2022, is one of 3 with no phase, and was the 9th registered.
568 studies on the registry are indexed under Edema; 97 are open to participants now.
Browse Edema studies →2 of the 13 studies in Edema with a site in Spain are open now. Recruiting first, the newest first:
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Sites in Spain
Ages 18+
Indiana University · Sites in Spain, United States, Argentina and 30 more countries
Ages 0 min–2 wk
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 56 Edema studies recruiting now, 34 (61%) set no upper age limit and 16 (29%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 54 across 402 interventional studies indexed under Edema.
Median enrollment 345 across the 9 interventional studies, 1,103 across the 4 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 13 have an industry lead sponsor. The 10 most frequent:
This study is registered under Firstkind Ltd, one of the names counted as Sky Medical Technology. Under that name alone:
Firstkind Ltd is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
Sky Medical Technology has 4 studies filed under Edema — fewer than ten, so there is no comparison to draw.
2 of the studies in Edema with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07484009Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Edema with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The multicentre randomised geko™ Foot and Ankle Trial will prospectively and systematically collect clinical data on patients randomised, on a 1:1 basis, to either standard care or standard care plus geko™ therapy to assess oedema management and patient outcomes during a follow-up period of up to three months post-surgery.
The geko™ device has a wide range of clinical applications including the post-operative management of oedema.
Although many short-term acute studies have been completed using the device, little clinical data has been collected on the effect of geko™ use in current standard care pathways for oedema management on patient outcomes during long term follow-up after surgery.
This study is an open label, multi-centre prospective randomised study. The study patient population will be randomised on a 1:1 basis into two groups of 61 patients each. These groups are defined as Group A patients who receive geko™ therapy and SC i.e. the intervention group and Group B patients who receive Standard Care (SC) only i.e. no intervention. The participants will be assessed pre-surgery and up to 90 days post-surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In addition to their standard of care, for patients randomised to the intervention arm, geko™ therapy will be applied immediately post-surgery on the operated leg and administered for 24 hours / day whilst the patient remains in hospital, after which geko™ therapy will then be applied for 12hrs / day until the patient returns for their first post-operative follow-up visit (Day 14 ± 2 days post-surgery)
Device: geko™ therapy
Patients will receive their standard of care as per hospital practice.
Neuro-muscular electrical stimulation of the peroneal nerve
Also known as: geko, NMES
Assessment of Post-operative Oedema Formation Using the Figure-of-eight Tape Measurement
To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery. This will be done using the figure of eight tape measurement method
Time frame: Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
Assessment of Post-operative Oedema Formation Using the Pitting Oedema Scale
To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery using the pitting oedema scale, where following a 2 second firm thumb press, 0 (min) indicates no oedema and 4 (max) is a very deep pit.
Time frame: Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
Assessment of Post-operative Oedema Formation Using Bioimpedance Analysis (US Sites Only)
To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery using a bioimpedance device to measure resistance to electrical current in both legs and calculating the percentage difference between the operated leg and the contralateral limb.
Time frame: Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
Adverse Events
Incidence of Adverse Events in each group
Time frame: From pre-surgery assessment until up to 90 days post-surgery
Device Deficiencies
To assess the number of geko device deficiencies (if any)
Time frame: from start of geko treatment (immediately post-surgery) until up to 90 days post-surgery
Change in Pain Level Using a Visual Analogue Scale (VAS) Score
Assessing pain levels using a visual analogue scale (VAS) score, where 0mm means no pain and 100mm is the worst pain possible.
Time frame: Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
Surgical Wound Healing
Visually assessing the surgical wound healing status as either healed/progressing/static/deteriorating/severe.
Time frame: From surgery until up to 90 days post-surgery
Change in Analgesia Dosage
Assessing changes in dosage of recorded analgesic medication taken by the patient
Time frame: From pre-surgery assessment until up to 90 days post-surgery
Change in Analgesia Frequency
Analgesic medication use was recorded; however, participants were not asked to record the frequency of use. Therefore, frequency of analgesic use could not be analysed.
Time frame: From pre-surgery assessment until up to 90 days post-surgery
Change in Patient Reported Outcomes Via Manchester-Oxford Foot & Ankle Questionnaire (MOxFQ)
Domains that are assessed in this questionnaire include walking/standing, pain and social interaction. Scores will range from 0 to 100, where 100 is most severe.
Time frame: Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
| Milestone | Standard of Care + Geko™ Therapy | Standard of Care |
|---|---|---|
| Started | 58 | 53 |
| Completed | 43 | 35 |
| Not completed | 15 | 18 |
To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery. This will be done using the figure of eight tape measurement method
| cm | Standard of Care + Geko™ Therapy | Standard of Care |
|---|---|---|
| Baseline-pre-op | 52.51 ± 0.7 | 52.49 ± 0.56 |
| FU1- Day 14 post-op | 53.74 ± 0.81 | 54.9 ± 0.82 |
| FU2- Day 42 post-op | 52.74 ± 0.74 | 53.97 ± 0.76 |
| FU3- Day 90 post-op | 52.75 ± 0.67 | 53.37 ± 0.7 |
To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery using the pitting oedema scale, where following a 2 second firm thumb press, 0 (min) indicates no oedema and 4 (max) is a very deep pit.
| score | Standard of Care + Geko™ Therapy | Standard of Care |
|---|---|---|
| Baseline (pre-op) | 0.21 ± 0.06 | 0.14 ± 0.06 |
| FU1 (Day 14 post-op) | 0.33 ± 0.07 | 0.5 ± 0.09 |
| FU2 (Day 42 post-op) | 0.16 ± 0.06 | 0.28 ± 0.09 |
| FU3 (Day 90 post-op) | 0.2 ± 0.06 | 0.23 ± 0.07 |
To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery using a bioimpedance device to measure resistance to electrical current in both legs and calculating the percentage difference between the operated leg and the contralateral limb.
| percent | Standard of Care + Geko™ Therapy | Standard of Care |
|---|---|---|
| Baseline (pre-op) | -0.86 ± 1.37 | 1.04 ± 2.51 |
| FU1 (Day 14 post-op) | 6.15 ± 2.22 | 8.97 ± 1.61 |
| FU2 (Day 42 post-op) | 8.23 ± 2.64 | 7.43 ± 1.58 |
| FU3 (Day 90 post-op) | 4.53 ± 1.4 | 5.58 ± 1.66 |
Incidence of Adverse Events in each group
| events | Standard of Care + Geko™ Therapy | Standard of Care |
|---|---|---|
| Adverse events | 20 | 13 |
| Adverse Device Events | 10 | 0 |
| Serious Adverse Events | 4 | 2 |
| Serious Adverse Device Events | 0 | 0 |
To assess the number of geko device deficiencies (if any)
| events | Standard of Care + Geko™ Therapy |
|---|---|
| Device Deficiencies | 11 |
Assessing pain levels using a visual analogue scale (VAS) score, where 0mm means no pain and 100mm is the worst pain possible.
| mm | Standard of Care + Geko™ Therapy | Standard of Care |
|---|---|---|
| Baseline (pre-op) | 39.02 ± 4.32 | 41.24 ± 4.82 |
| FU1 (Day 14 post-op) | 30.54 ± 3.33 | 34.31 ± 4.11 |
| FU2 (Day 42 post-op) | 22.32 ± 3.47 | 16.52 ± 2.82 |
| FU3 (Day 90 post-op) | 22.08 ± 3.71 | 16.71 ± 3.69 |
Visually assessing the surgical wound healing status as either healed/progressing/static/deteriorating/severe.
| Participants | Standard of Care + Geko™ Therapy | Standard of Care |
|---|---|---|
| Healed | 22 | 12 |
| Progressing | 21 | 22 |
| Static | 0 | 1 |
| Deteriorating | 0 | 0 |
| Severe | 0 | 0 |
Assessing changes in dosage of recorded analgesic medication taken by the patient
| Measure | Standard of Care + Geko™ Therapy | Standard of Care |
|---|---|---|
| Change in Analgesia Dosage | NA | NA |
Analgesic medication use was recorded; however, participants were not asked to record the frequency of use. Therefore, frequency of analgesic use could not be analysed.
| analgesia uses | Standard of Care + Geko™ Therapy | Standard of Care |
|---|---|---|
| Change in Analgesia Frequency | NA | NA |
Domains that are assessed in this questionnaire include walking/standing, pain and social interaction. Scores will range from 0 to 100, where 100 is most severe.
| score | Standard of Care + Geko™ Therapy | Standard of Care |
|---|---|---|
| Baseline (pre-op) | 55.36 ± 3.28 | 50.26 ± 4.3 |
| FU1 (Day 14 post-op) | 59.27 ± 3.78 | 46.63 ± 4.05 |
| FU2 (Day 42 post-op) | 48.87 ± 3.36 | 43.75 ± 4.7 |
| FU3 (Day 90 post-op) | 39.72 ± 3.81 | 36.14 ± 4.09 |
Collected over From enrollment until end of follow up (up to 90 days post-surgery). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard of Care + Geko™ Therapy | 0/58 (0%) | 2/58 (3.4%) | 23/58 (39.7%) |
| Standard of Care | 0/53 (0%) | 2/53 (3.8%) | 10/53 (18.9%) |
| Event | Standard of Care + Geko™ Therapy | Standard of Care |
|---|---|---|
| Nerve pain in operated footGeneral disorders | 2/58 | 0/53 |
| Surgical wound complicationsInjury, poisoning and procedural complications | 1/58 | 1/53 |
| Potential peripheral nerve damage in operated footInjury, poisoning and procedural complications | 0/58 | 1/53 |
| Opioid induced nauseaGastrointestinal disorders | 1/58 | 0/53 |
| Event | Standard of Care + Geko™ Therapy | Standard of Care |
|---|---|---|
| Rash or irritation at device application siteSkin and subcutaneous tissue disorders | 9/58 | 0/53 |
| Post-operative pain and/or swellingInjury, poisoning and procedural complications | 6/58 | 6/53 |
| Surgical wound complicationsInjury, poisoning and procedural complications | 3/58 | 2/53 |
| FallInjury, poisoning and procedural complications | 3/58 | 0/53 |
| Parasthesia in operated footGeneral disorders | 2/58 | 1/53 |
| Urinary tract infectionInfections and infestations | 0/58 | 1/53 |
| Bruising on operated footInjury, poisoning and procedural complications | 0/58 | 1/53 |
| Abdominal painGastrointestinal disorders | 0/58 | 1/53 |
| Rash on operated footSkin and subcutaneous tissue disorders | 1/58 | 0/53 |
| Opioid induced nauseaGastrointestinal disorders | 1/58 | 0/53 |
| Age, Customized(years) | Standard of Care + Geko™ Therapy | Standard of Care | Total |
|---|---|---|---|
| Age at enrollment | 52.03 ± 14.43 | 53.79 ± 15.88 | 52.87 ± 15.10 |
| Sex: Female, Male(Participants) | Standard of Care + Geko™ Therapy | Standard of Care | Total |
|---|---|---|---|
| Female | 44 | 37 | 81 |
| Male | 14 | 16 | 30 |
| Race and Ethnicity Not Collected(Participants) | Standard of Care + Geko™ Therapy | Standard of Care | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Standard of Care + Geko™ Therapy | Standard of Care | Total |
|---|---|---|---|
| United States | 12 | 12 | 24 |
| United Kingdom | 21 | 19 | 40 |
| Spain | 25 | 22 | 47 |
| BMI(kg/m^2) | Standard of Care + Geko™ Therapy | Standard of Care | Total |
|---|---|---|---|
| Mean | 27.37 ± 5.06 | 29.23 ± 6.74 | 28.26 ± 5.97 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2022 to primary completion in Jul 2024, 21 months.
Results were first posted in Oct 2026, 2 years 2 months after primary completion.
Of 168 interventional studies with no phase under Edema, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's 21 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.